MedTrace Logo

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

NCT05501860 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2024-10-09

Study results available
· View outcomes & findings →

Summary

A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..

Conditions

  • Anesthesia, Local

Interventions

DRUG

AG-920

AG-920 Sterile Topical Ophthalmic Solution

DRUG

Placebo

Placebo Sterile Topical Ophthalmic Solution

Sponsors & Collaborators

  • American Genomics, LLC

    lead INDUSTRY

Principal Investigators

  • Martin Uram, MD · Medical Expert

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-30
Primary Completion
2022-12-07
Completion
2022-12-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05501860 on ClinicalTrials.gov